Proteros biostructures GmbH announces an expansion of its collaboration with AstraZeneca focused on the discovery and development of novel epigenetic drugs. The new multi-year agreement builds on an ongoing collaboration with AstraZeneca announced [2] in June 2021, to include the development of small molecule inhibitors targeting a second cancer-associated epigenetic protein. Under the terms of this new agreement, Proteros will receive research funding and will be eligible for success-based research, development, and commercial milestone payments of up to USD 75 million plus tiered royalties on annual net sales.

The collaboration combines Proteros' expertise in the identification and characterization of inhibitors with novel binding mechanisms for technically challenging drug targets with AstraZeneca's leadership in the discovery and development of oncology medicines.